Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections
Notice type:
Advisory
Date:
01/08/2008
Product name or type:
Norfloxacin
Active Substance:
Norfloxacin
Problem Or Issue:
The European Medicines Agency has recommended restricting the use of oral norfloxacin-containing medicines in urinary infections. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the marketing authorisations for oral norfloxacin-containing medicines, when used in the treatment of acute or chronic complicated pyelonephritis (kidney infection), should be withdrawn because the benefits of these medicines do not outweigh their risks in this indication. This is based on the fact that the efficacy has not been adequately demonstrated for this type of infection.
Background Information Or Related Documents:
EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections Document
Further Information:
For further information,
Click Here to read the Press Release
.
« Back
Date Printed: 19/04/2024